ES2736121T3 - Combinación de lenalidomida y constructo polipeptídico, y usos de los mismos - Google Patents

Combinación de lenalidomida y constructo polipeptídico, y usos de los mismos Download PDF

Info

Publication number
ES2736121T3
ES2736121T3 ES15799475T ES15799475T ES2736121T3 ES 2736121 T3 ES2736121 T3 ES 2736121T3 ES 15799475 T ES15799475 T ES 15799475T ES 15799475 T ES15799475 T ES 15799475T ES 2736121 T3 ES2736121 T3 ES 2736121T3
Authority
ES
Spain
Prior art keywords
antibody
combination
lenalidomide
attenuated
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15799475T
Other languages
English (en)
Spanish (es)
Inventor
Sarah L Pogue
David S Wilson
Anthony Gerard Doyle
Collette Jane Behrens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Application granted granted Critical
Publication of ES2736121T3 publication Critical patent/ES2736121T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES15799475T 2014-05-01 2015-05-01 Combinación de lenalidomida y constructo polipeptídico, y usos de los mismos Active ES2736121T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986913P 2014-05-01 2014-05-01
PCT/IB2015/001600 WO2015181641A2 (en) 2014-05-01 2015-05-01 Combination of lenalidomide and polypeptide construct, and uses thereof

Publications (1)

Publication Number Publication Date
ES2736121T3 true ES2736121T3 (es) 2019-12-26

Family

ID=54354398

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15799475T Active ES2736121T3 (es) 2014-05-01 2015-05-01 Combinación de lenalidomida y constructo polipeptídico, y usos de los mismos

Country Status (19)

Country Link
US (3) US9636334B2 (enExample)
EP (1) EP3137505B1 (enExample)
JP (1) JP6550400B2 (enExample)
KR (1) KR102412023B1 (enExample)
CN (1) CN106536562B (enExample)
AU (1) AU2015265624B2 (enExample)
BR (1) BR112016025437A2 (enExample)
CA (1) CA2945902C (enExample)
CL (1) CL2016002733A1 (enExample)
EA (1) EA033359B1 (enExample)
ES (1) ES2736121T3 (enExample)
IL (1) IL248394B (enExample)
MA (1) MA39836A (enExample)
MX (1) MX375746B (enExample)
NZ (1) NZ725487A (enExample)
PE (1) PE20161392A1 (enExample)
PT (1) PT3137505T (enExample)
UA (1) UA119352C2 (enExample)
WO (1) WO2015181641A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) * 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
BR112019000544A2 (pt) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
CN111278858B (zh) 2017-07-11 2024-07-23 指南针制药有限责任公司 结合人cd137的激动剂抗体及其用途
CN111328286B (zh) 2017-08-09 2024-08-23 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
KR102659140B1 (ko) 2017-08-09 2024-04-19 오리오니스 바이오사이언시스 인코포레이티드 Clec9a 결합제 및 그의 용도
CA3069930A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Cd8 binding agents
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3737702A1 (en) 2018-01-12 2020-11-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
KR102286497B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 다양한 용량의 레날리도마이드의 경구용 정제 조성물
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
JP7581052B2 (ja) * 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
RU2694672C1 (ru) * 2018-04-27 2019-07-16 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против интерферона альфа (IFN-α) человека, антигенсвязывающий фрагмент (Fab) против IFN-α человека, содержащий указанные домены
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
EP3947429A4 (en) 2019-03-28 2023-05-17 Orionis Biosciences, Inc. CLEC9A-BASED CHIMERA PROTEIN COMPLEXES
CN113993543B (zh) 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
JP2023505168A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インターフェロン会合抗原結合タンパク質及びこれらの使用
EP4525911A1 (en) 2022-05-18 2025-03-26 Takeda Pharmaceutical Company Limited Anti-cd38 fusion protein formulation
WO2023227949A1 (en) * 2022-05-27 2023-11-30 Takeda Pharmaceutical Company Limited Dosing of cd38-binding fusion protein
TW202430548A (zh) * 2022-09-29 2024-08-01 日商武田藥品工業股份有限公司 Ｃｄ３８結合融合蛋白組合療法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
JP3854306B2 (ja) 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2191702T3 (es) 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
DK0706799T3 (da) 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CN1217750A (zh) 1996-05-04 1999-05-26 曾尼卡有限公司 抗cea的单克隆抗体,包括所述抗体的偶联物及其在adept系统中的治疗应用
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
MXPA01003790A (es) 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
DK1137789T3 (da) 1998-12-09 2010-11-08 Phyton Holdings Llc Fremgangsmåde til fremstilling af et glycoprotein med glycosylering af human type
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
JP4778617B2 (ja) 1999-03-12 2011-09-21 ジョージタウン ユニバーシティ マトリプターゼ、セリンプロテアーゼおよびその応用
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
WO2001097844A1 (en) 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ES2330330T3 (es) 2000-06-28 2009-12-09 Glycofi, Inc. Procedimiento de produccion de glucoproteinas modificadas.
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DK1409544T3 (da) 2001-07-03 2009-10-26 Genentech Inc Humane DR4-antistoffer og anvendelser deraf
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
KR100668538B1 (ko) 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ES2350477T5 (es) 2002-03-01 2020-05-06 Immunomedics Inc Internalización de anticuerpos anti-CD74 y métodos de uso
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
ES2343518T3 (es) 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
CA2498284A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2516293A1 (en) 2003-02-18 2004-09-02 Tim Jones Fusion proteins of interferon alpha muteins with improved properties
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP5222559B2 (ja) 2004-10-15 2013-06-26 シアトル ジェネティックス， インコーポレイテッド 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
EP2799451A1 (en) * 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
CN101184771A (zh) 2005-05-26 2008-05-21 先灵公司 干扰素－IgG融合体
AU2006263331B2 (en) 2005-06-29 2012-02-16 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Recombinant interferon alpha2 (IFNalpha2) mutants
EA021669B1 (ru) 2005-07-18 2015-08-31 Амджен Инк. Нейтрализующие антитела человека против b7rp1
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US20070190068A1 (en) 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
RU2425841C2 (ru) 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
JP2009513147A (ja) 2005-10-31 2009-04-02 アメリカ合衆国 ヒト糖タンパクｎｍｂをターゲットにする抗体および免疫毒素
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
CN101045156B (zh) 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
FR2905375A1 (fr) 2006-08-29 2008-03-07 Biomethodes Sa Variants ameliores de l'interferon alpha humain
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
HRP20191115T1 (hr) * 2006-09-26 2019-09-20 Genmab A/S Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7723485B2 (en) 2007-05-08 2010-05-25 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
CA2695382A1 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of A fold-back diabody diphtheria toxin immunotoxin and methods of use
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
EP3150218B1 (en) 2007-09-21 2021-09-08 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20100261275A1 (en) 2007-12-10 2010-10-14 Yves Durocher Production of Recombinant Interferon Proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
HRP20140604T1 (hr) 2007-12-26 2014-09-12 Biotest Ag Sredstva koja djeluju na cd138 i njihova upotreba
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
MA33194B1 (fr) 2009-03-16 2012-04-02 Cephalon Australia Pty Ltd Anticorps humanisés ayant une activité antitumorale
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
US8909257B2 (en) 2010-06-19 2014-12-09 Qualcomm Incorporated Positioning protocol conveyance
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
US9505826B2 (en) 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US9492562B2 (en) 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US20150353485A1 (en) 2013-01-25 2015-12-10 Bayer Materialscience Ag Security element having volume hologram and printed feature
NZ713641A (en) 2013-04-29 2019-08-30 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) * 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b

Also Published As

Publication number Publication date
WO2015181641A3 (en) 2016-01-21
PT3137505T (pt) 2019-07-17
US20170202962A1 (en) 2017-07-20
PE20161392A1 (es) 2017-01-04
US20150313965A1 (en) 2015-11-05
AU2015265624B2 (en) 2021-02-18
MX375746B (es) 2025-03-06
EP3137505B1 (en) 2019-04-24
IL248394B (en) 2020-05-31
EA033359B1 (ru) 2019-10-31
CA2945902C (en) 2023-10-03
EP3137505A4 (en) 2017-11-29
KR102412023B1 (ko) 2022-06-21
KR20160146770A (ko) 2016-12-21
NZ725487A (en) 2020-05-29
CL2016002733A1 (es) 2017-06-23
MX2016013863A (es) 2017-07-24
AU2015265624A1 (en) 2016-11-10
BR112016025437A2 (pt) 2017-12-12
MA39836A (fr) 2017-03-08
IL248394A0 (en) 2016-11-30
US20190151447A1 (en) 2019-05-23
JP2017515815A (ja) 2017-06-15
JP6550400B2 (ja) 2019-07-24
CA2945902A1 (en) 2015-12-03
WO2015181641A2 (en) 2015-12-03
CN106536562B (zh) 2023-04-14
US9636334B2 (en) 2017-05-02
US10232041B2 (en) 2019-03-19
US11253591B2 (en) 2022-02-22
CN106536562A (zh) 2017-03-22
UA119352C2 (uk) 2019-06-10
EP3137505A2 (en) 2017-03-08
EA201692200A1 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
ES2736121T3 (es) Combinación de lenalidomida y constructo polipeptídico, y usos de los mismos
US20200392239A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
BR112019021182A2 (pt) Agentes de anticorpo anti-cd33
CN110612309A (zh) 用于降低免疫原性的方法和组合物
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
BR112021007134A2 (pt) terapia combinada para câncer
TW202222823A (zh) 投與治療劑量的雙特異性ｔ細胞接合分子治療癌症之方法
TW202440636A (zh) Ｃｄ１９／ｃｄ３８多特異性抗體
KR20240115809A (ko) 활성화 가능한 폴리펩타이드 복합체
TW202028226A (zh) Ｉｌ－１５蛋白複合物聯合ｐｄ－ｌ１抗體用於治療腫瘤疾病的用途
US20230057939A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
US20250270316A1 (en) Pharmaceutical combination and use thereof
US20250282871A1 (en) Pharmaceutical combination and use thereof
TW202034925A (zh) Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
TW202019962A (zh) 標靶CD38及TGF-β的組合療法
JP7371093B2 (ja) 腫瘍および／または転移の治療のための抗－ｍｅｔ ｆａｂ－ｆｃ
CA3163865A1 (en) Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
HK1235070B (en) Combination of lenalidomide and polypeptide construct, and uses thereof
HK1235070A1 (en) Combination of lenalidomide and polypeptide construct, and uses thereof
WO2024041651A1 (en) Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies
CN118103406A (zh) 可激活多肽复合物
WO2025056014A1 (zh) 包含抗pd-1抗体和第二抗体的药物组合物
WO2023025303A1 (zh) 抗cldn-18.2抗体药物偶联物及其用途
HK1172823A (en) Cd40 antibody formulation and methods
NZ715807B2 (en) Polypeptide constructs and uses thereof